Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties

SAN DIEGO, Sept. 14, 2017 -- (Healthcare Sales & Marketing Network) -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today it licensed its ENHANZE® drug-delivery technology to Roche for exclusive development of an undisclosed therapeutic target... Biopharmaceuticals, Drug Delivery, Licensing Halozyme Therapeutics, Roche Group, ENHANZE

Source: HSMN NewsFeed - September 14, 2017 Category: Pharmaceuticals Source Type: news